Quality of Life and Volume Reduction in Women with Secondary Lymphoedema Related to Breast Cancer

Table 3

Linear regression model between the score of quality of life at baseline and percentage reduction of excess volume between the upper limb after treatment.

Quality of life	Mean (SD)	Simple linear regression
		Beta (CI 95%)	value
EORTC QLQ C30
Functional scale
Physical function	70.39 (21.39)	−0.05 (−0.22–0.12)	0.591
Performing roles	71.16 (33.50)	0.03 (−0.07–0.14)	0.520
Cognitive function	63.43 (28.95)	0.01 (−0.11–0.14)	0.826
Emotional function	54.82 (31.31)	−0.05 (−0.17–0.06)	0.388
Social function	89.42 (19.54)	−0.01 (−0.20–0.18)	0.917
Symptoms scale
Dyspnea	82.70 (33.31)	0.05 (−0.05–0.16)	0.318
Pain	65.72 (35.90)	0.00 (−0.10–0.10)	0.992
Fatigue	68.37 (30.83)	−0.03 (−0.15–0.08)	0.563
Insomnia	76.29 (36.29)	−0.04 (−0.14–0.05)	0.372
Loss of appetite	92.30 (19.38)	0.01 (−0.17–0.20)	0.878
Nausea and vomiting	92.63 (14.54)	0.09 (−0.16–0.34)	0.486
Constipation	83.33 (31.30)	−0.04 (−0.15–0.08)	0.505
Diarrhea	94.87 (19.10)	−0.02 (−0.21–0.17)	0.863
Financial hardship	76.94 (38.20)	0.07 (−0.02–0.16)	0.139
Overall quality of life	40.20 (29.18)	0.02 (−0.10–0.15)	0.728
BR23
Functional scale
Body image	76.37 (29.02)	0.01 (−0.11–0.14)	0.826
Future perspective	47.28 (40.90)	−0.03 (−0.12–0.05)	0.448
Sexual function	76.06 (25.00)	0.00 (−0.14–0.15)	0.951
Symptoms scale
Systemic therapy	75.24 (20.23)	0.08 (−0.10–0.25)	0.385
Arm symptoms	53.34 (27.16)	−0.11 (−0.24–0.02)	0.099
Breast symptoms	83.49 (21.36)	−0.00 (−0.17–0.17)	0.994